HomeStock ScreenerBacil Pharma

Bacil Pharma Share Price | Bacil Pharma Stock Screener

BACPHAR Pharmaceuticals
Share Price BSE
₹39.85
▼ -0.26 (-0.65%)
2026-07-03 00:00:00
As of July 3, 2026, the Bacil Pharma share price (BSE: BACPHAR) is ₹39.85, down 0.65% from the previous close, with shares trading between ₹38.31 and ₹40.11, and a 52-week range of ₹28.09–₹59.89. Analyse BACPHAR stock price history and track historical price performance. Use the Bacil Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Bacil Pharma Market Cap ₹57.20 Cr.
BACPHAR P/E Ratio (TTM) 36.90
Bacil Pharma P/B Ratio 2.27
EPS (TTM) ₹1.11
Dividend Yield -
Debt to Equity 0.01
BACPHAR 52 Week High ₹59.89
Bacil Pharma 52 Week Low ₹28.09
Operating Margin -
Profit Margin -
BACPHAR Revenue (TTM) -
EBITDA -
Net Income ₹1.00
Total Assets ₹27.00
Total Equity ₹25.00

Bacil Pharma Share Price Chart

Screen Bacil Pharma share price with an interactive chart. Analyse BACPHAR price trends and volatility across different timeframes.

Bacil Pharma Company Profile - Fundamental Screener

Screen Bacil Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BACPHAR shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE711D01018

Bacil Pharma Balance Sheet Screener

Screen BACPHAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017
Assets
Total Assets 27 26 1 1 1 4 4 5 5 7
Current Assets 2 3 0 0 0 0 0 1 1 0
Fixed Assets 0 0 0 0 0 3 3 3 3 6
Liabilities
Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 25 25 1 1 1 1 1 2 2 6
Share Capital 14 14 7 7 7 7 7 7 7 7
Reserves & Surplus 11 12 -5 -5 -5 -5 -5 -5 -4 0

Bacil Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Bacil Pharma income statement and profit fundamentals. Analyze BACPHAR quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Bacil Pharma share price evaluation.
Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March
Revenue 0 1 0 0 0 0 0 0 0 0 0 0
Expenses 0 0 0 0 4 0 1 0 0 0 0 0
EBITDA 0 0 0 0 -4 0 0 0 0 0 0 0
Operating Profit % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 0 0 0 -4 0 0 0 -4 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 1 0 0 0 -4 0 0 0 -4 0 0 0
EPS 1.11 0.64 -0.10 -0.17 -6.55 -0.41 -0.54 -0.58 -6.37 0.00 -0.11 -0.05

Bacil Pharma Cash Flow Screener - Liquidity Fundamentals

Screen BACPHAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 0 0 0 -4 0 0 0 1 0 0
Investing Activities 0 0 0 4 1 0 0 -1 0 0
Financing Activities 2 0 0 0 0 0 0 0 0 0
Net Cash Flow 3 0 0 0 0 0 0 0 0 0

Bacil Pharma Shareholding Pattern Screener

See Bacil Pharma shareholding pattern with promoter, FII, and DII holdings. Check Bacil Pharma promoter holding and ownership changes for BACPHAR on TickJournal.
Item 2026-Mar 2025-Mar 2025-Jun 2025-Jul 2025-Sept 2025-Dec 2024-Mar 2024-Jun
Promoter Holding 0.00% 0.20% 0.20% 0.08% 0.08% 0.08% 42.67% 42.67%
FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 98.26% 75.77% 77.37% 79.74% 80.95% 80.95% 53.89% 53.91%
Other Holding 1.74% 24.03% 22.43% 20.18% 18.97% 18.97% 3.44% 3.42%
Shareholder Count 7,226 7,638 7,532 7,541 7,431 7,431 6,770 6,794

Bacil Pharma Share Dividend Screener - Share Yield Analysis

Check Bacil Pharma dividend history with payout and yield data. View Bacil Pharma dividend details including ex-dates and amounts for BACPHAR stock.
No dividends declared by Bacil Pharma.

Bacil Pharma Stock Index Membership

See which indices include Bacil Pharma stock. Check BACPHAR index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Bacil Pharma is not part of any tracked indices.
Only major market indices are tracked in our system.

Bacil Pharma Market Events Screener - Corporate Actions

Get Bacil Pharma corporate actions including splits, bonuses, and buybacks. Check Bacil Pharma stock events that may affect BACPHAR share price.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA 15.34%
Annual General Meeting NA 31.36%
2026-05-22 2026-05-22 Quarterly Result Announcement NA -5.53%
2026-02-13 2026-02-13 Quarterly Result Announcement NA 7.69%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -6.67%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -0.21%
2025-05-26 2025-05-26 Quarterly Result Announcement NA 0.00%
2025-01-21 2025-01-21 Quarterly Result Announcement NA -8.02%
2024-11-14 2024-11-14 Extraordinary General Meeting NA 26.52%
2024-10-23 2024-10-23 Quarterly Result Announcement NA 10.34%

Bacil Pharma Competitors Screener - Peer Comparison

Screen BACPHAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 457,025 39.71 58,220 6.38% 11,565 69.58
Divis Laboratories 179,377 69.89 10,560 8.73% 2,520 55.41
Torrent Pharmaceuticals 161,381 75.43 13,886 20.34% 2,138 70.39
Cipla 117,800 30.51 29,045 2.24% 3,870 66.80
Zydus Life Science 114,771 22.41 26,720 13.65% 5,242 66.88
Dr Reddys Laboratories 114,692 27.60 35,059 3.90% 4,158 67.04
Lupin 113,211 21.14 27,488 19.98% 5,345 71.73
Mankind Pharma 104,430 53.93 14,278 12.03% 1,750 60.79
Aurobindo Pharma 93,240 26.86 33,385 3.21% 3,376 70.76
Laurus Labs 83,262 93.55 6,868 22.01% 890 71.63

Bacil Pharma Company Announcements - News Screener

Screen BACPHAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-07-05 Board Meeting Intimation for We Hereby Inform You That A Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Thursday 9Th July 2026 -
2026-07-02 Intimation For Appointment Of Independent Director -
2026-07-01 Withdrawal Of Intimation For Appointment Of Independent Directors -
2026-07-01 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-07-01 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2026-06-28 Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On 26Th June 2026 Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-06-27 Closure of Trading Window -
2026-06-25 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-24 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-23 Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-06-18 Intimation Of Proposed Incorporation Of Wholly-Owned Subsidiary -
2026-06-13 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-11 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-06-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-28 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-22 Company Has Not Entered Any Related Party Transactions During The Half Year Ended 31St March 2026. -
2026-05-22 Statement Of Deviation Or Variation In Utilization Of Funds Under Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Is Not Applicable To The Company For The Quarter Ended 31St March 2026. -
2026-05-22 Audited Financial Results For 31St March 2026 -
2026-05-22 Board Meeting Outcome for Outcome Of Board Meeting For Audited Results For 31St March 2026 -
2026-05-11 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 22Nd May 2026 -